02 May
2024
ANANDA DEVELOPMENTS
PLC
("Ananda"
or the "Company")
Response to FSA-FSS
Cannabidiol Safety Assessment
Ananda Developments plc (AQSE: ANA),
a company focused on becoming a leading provider of regulator
approved CBD-based medicines for chronic pain conditions, notes the
Food Standards Agency's (FSA) and Food Standards Scotland's (FSS)
recently published
Safety Assessment: "Cannabidiol (CBD) isolate
as a novel food for use in a range of food categories including
food supplements".
Ananda believes that the FSA-FSS
assessment underscores its strategy of developing
CBD formulations as licensed medicines, with Randomised Controlled
Trials evidence, to allow for accurate and potentially higher
doses. With the FSA-FFS paper advocating for a maximum daily
intake of 10mg of CBD in food supplements, it is likely that
therapeutic doses of CBD may solely be accessible for the majority
of people through NHS prescription.
Ananda's patent pending MRX1 CBD
formulation will be trialled in two Phase II trials, investigating
the pain relieving effects of MRX1 on sufferers of endometriosis
and Chemotherapy Induced Peripheral Neuropathy
("CIPN"), which demonstrate how Ananda's
strategy aligns with the FSA's recommendations.
Ananda CEO, Melissa Sturgess, commented:
"We identified several years ago that the right path to build
shareholder value in the CBD space is via clinical trials, evidence
and regulatory approvals. This latest FSA-FSS report highlights
that we were correct in our assessment, and we look forward to
delivering the results of our clinical trials and further
initiatives in this area."
Read
the assessment in full here:
https://www.food.gov.uk/sites/default/files/media/document/safety-assessment-cannabidiol-isolate-as-a-novel-food.pdf
|
For
more information please contact:
InvestorHub
Engage with us directly at Ananda
Developments Investor Hub
|
Sign up at https://investors.anandadevelopments.com/s/a66906
|
|
ANANDA DEVELOPMENTS PLC
Chief Executive Officer
Melissa Sturgess
Executive Director
Jeremy Sturgess-Smith
|
+44 (0)7463 686 497
ir@anandadevelopments.com
|
|
SP
ANGEL CORPORATE FINANCE LLP
Corporate Finance
Richard Morrison
Caroline Rowe
|
+44 (0)20 3470 0470
|
|
Corporate Broking
Abigail Wayne
Rob Rees
|
|
|
Yellow Jersey PR
Charles Goodwin
Zara McKinlay
|
+44 (0)20 3004 9512
|
About Ananda Developments
Ananda is an AQSE-listed company
whose ambition is to be a leading provider of
cannabinoid-based
medicines for the treatment of
complex, chronic inflammatory pain conditions.
For further information on the
Company visit https://anandadevelopments.com/
or sign up at https://investors.anandadevelopments.com/s/a66906.
https://investors.anandadevelopments.com/link/Dexlke